Synthesis and in vitro evaluation of three 99mTc-labeled hydroxamamide-based ligands as markers for hypoxic cells

被引：7
作者：
Chu, Taiwei [1 ]
Xu, Hong [1 ]
Yang, Zhi [2 ,3 ]
Wang, Xiangyun [1 ]
机构：
[1] Peking Univ, BNLMS, Dept Appl Chem, Coll Chem & Mol Engn, Beijing 100871, Peoples R China
[2] Peking Univ, Sch Oncol, Beijing 100036, Peoples R China
[3] Peking Univ, Beijing Inst Canc Res, Beijing 100036, Peoples R China
来源：
APPLIED RADIATION AND ISOTOPES | 2009年 / 67卷 / 04期
基金：
中国国家自然科学基金; 北京市自然科学基金;
关键词：
(99m)Tc complex; Hypoxia marker; Lipophilicity; Hydroxamamide; Labeling; TUMOR HYPOXIA; TC-99M RADIOPHARMACEUTICALS; TETRADENTATE LIGANDS;
D O I：
10.1016/j.apradiso.2008.12.003
中图分类号：
O61 [无机化学];
学科分类号：
070301 ; 081704 ;
摘要：
Three new hydroxamamide derivatives with different lipophilicity, N'-hydroxy-N-methyl-3-(4-nitro-1H-imidazol-1-yl)propanamidine, N-butyl-N'-hydroxy-3-(4-nitro-1H-imidazol-1-yl)propanamidine, and N'-hydroxy-3-(4-nitro-1H-imidazol-1-yl)-N-octadecyl propanamidine were easily synthesized and labeled with technetium-99m as markers for hypoxic cells. The results of in vitro experiment indicate that the accumulation of three (99m)Tc-complexes steadily increases with time in hypoxic cells, but fluctuates with time and has no fixed trend in aerobic cells; the complex with higher lipophilicity shows more uptake in cells; and the effect of lipophilicity of the (99m)Tc-complexes on the hypoxic/aerobic difference can be neglected. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：590 / 593
页数：4
相关论文
共 10 条
[1]   Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays [J].
Chapman, JD ;
Engelhardt, EL ;
Stobbe, CC ;
Schneider, RF ;
Gerald, GE .
RADIOTHERAPY AND ONCOLOGY, 1998, 46 (03) :229-237
[2]   Preparation and biodistribution of technetium-99m-labeled 1-(2-nitroimidazole-1-yl)-propanhydroxyimino amide (N21PA) as a tumor hypoxia marker [J].
Chu, TW ;
Li, RJ ;
Hu, SW ;
Liu, XQ ;
Wang, XY .
NUCLEAR MEDICINE AND BIOLOGY, 2004, 31 (02) :199-203
[3]   Synthesis and biological results of the technetium-99m-labeled 4-nitroimidazole for imaging tumor hypoxia [J].
Chu, TW ;
Hu, SW ;
Wei, B ;
Wang, Y ;
Liu, XQ ;
Wang, XY .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (03) :747-749
[4]   Synthesis and in vitro and in vivo evaluation of three radioiodinated nitroimidazole analogues as tumor hypoxia markers [J].
Li, ZJ ;
Chu, TW ;
Liu, XQ ;
Wang, XY .
NUCLEAR MEDICINE AND BIOLOGY, 2005, 32 (03) :225-231
[5]   HYDROXAMAMIDE AS A CHELATING MOIETY FOR THE PREPARATION OF TC-99M RADIOPHARMACEUTICALS .2. THE TC-99M COMPLEXES OF HYDROXAMAMIDE DERIVATIVES [J].
NAKAYAMA, M ;
SAIGO, H ;
KODA, A ;
OZEKI, K ;
HARADA, K ;
SUGII, A ;
TOMIGUCHI, S ;
KOJIMA, A ;
HARA, M ;
NAKASHIMA, R ;
OHYAMA, Y ;
TAKAHASHI, M ;
TAKATA, J ;
KARUBE, Y .
APPLIED RADIATION AND ISOTOPES, 1994, 45 (06) :735-740
[6]   NITROIMIDAZOLES AND IMAGING HYPOXIA [J].
NUNN, A ;
LINDER, K ;
STRAUSS, HW .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1995, 22 (03) :265-280
[7]   Facile synthesis of bis(hydroxamamide)-based tetradentate ligands for 99mTc-radiopharmaceutical [J].
Xu, H ;
Chu, TW ;
Wang, XG ;
Liu, XQ .
APPLIED RADIATION AND ISOTOPES, 2005, 62 (06) :919-922
[8]   Synthesis and evaluation of hydroxamamide-based tetradentate ligands as a new class of thiol-free chelating molecules for 99mTc radiopharmaceuticals [J].
Xu, LC ;
Nakayama, M ;
Harada, K ;
Nakayama, H ;
Tomiguchi, S ;
Kojima, A ;
Takahashi, M ;
Arano, Y .
NUCLEAR MEDICINE AND BIOLOGY, 1998, 25 (03) :295-303
[9]   Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: Effect of lipophilicity [J].
Zhang, XG ;
Su, ZF ;
Ballinger, JR ;
Rauth, AM ;
Pollak, A ;
Thornback, JR .
BIOCONJUGATE CHEMISTRY, 2000, 11 (03) :401-407
[10]   Synthesis and preliminary biological evaluation of the 99mTc labeled nitrobenzoimidazole and nitrotriazole as tumor hypoxia markers [J].
Zhang, Y ;
Chu, TW ;
Gao, XG ;
Liu, XQ ;
Yang, Z ;
Guo, ZQ ;
Wang, XY .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (07) :1831-1833
1